Yüklüyor......
Cytogenetic and molecular predictors of response in patients with myeloid malignancies without del[5q] treated with lenalidomide
BACKGROUND: While lenalidomide (LEN) shows high efficacy in myelodysplastic syndromes (MDS) with del[5q], responses can be also seen in patients presenting without del[5q]. We hypothesized that improved detection of chromosomal abnormalities with new karyotyping tools may better predict response to...
Kaydedildi:
| Asıl Yazarlar: | , , , , , , , , , , , , , , |
|---|---|
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
BioMed Central
2012
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3323440/ https://ncbi.nlm.nih.gov/pubmed/22390313 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1756-8722-5-4 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|